Press release
Meningioma Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Discover the latest drugs and treatment options in the Meningioma Pipeline. Dive into DelveInsight's comprehensive report today! @ Meningioma Pipeline Outlook [https://www.delveinsight.com/sample-request/meningioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Meningioma Pipeline Report
* In May 2025, European Organisation for Research and Treatment of Cancer - EORTC conducted a LUMEN-1 trial will investigate in a prospective randomized trial the efficacy of the precision medicine "theranostic" concept of combining diagnostic patient selection using PET-based molecular imaging and target-specific therapeutic intervention using a systemically administered radioligand.
* In May 2025, Baptist Health South Florida announced a phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma.
* DelveInsight's Meningioma Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Meningioma treatment.
* The leading Meningioma Companies such as NX Development Corp., Clarity Pharmaceutical Ltd., Bristol-Myers Squibb, Biosynthema Inc. , and others.
* Promising Meningioma Pipeline Therapies such as Nivolumab, Cabozantinib, Abemaciclib, SOM230C, Bevacizumab, 177Lu-DOTATATE, Pembrolizumab and others.
Stay ahead with the most recent pipeline outlook for Meningioma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Meningioma Treatment Drugs [https://www.delveinsight.com/sample-request/meningioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Meningioma Emerging Drugs Profile
* Gleolan: NX Devolopment Corp
NX development corp.'s drug, Gleolan also known as Aminolevulinic acid is an orally administered small molecule in development for the treatment and real time detection of meningioma. Gleolan is a prodrug that is metabolized intracellularly to form the fluorescent molecule Protoporphyrin IX (PpIX). The exogenous application of ALA leads to a highly selective accumulation of PpIX in tumor cells. Following excitation with blue light. It is a photosensitizer molecule which can utilize the energy to induce photochemical reactions to produce lethal toxic agents; ultimately results in cell death and tissue destruction.
* Nivolumab: Bristol-Myers Squibb
Bristol-Myers Squibb "breakthrough" drug nivolumab is currently being evaluated for the treatment of Meningioma and has demonstrated good safety and efficacy profile in phase II trials. Nivolumab is a human immunoglobin (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks the interaction with PD-L1 and PD-L2, releasing anti-tumor response.
The Meningioma Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Meningioma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Meningioma Treatment.
* Meningioma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Meningioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Meningioma market
Explore groundbreaking therapies and clinical trials in the Meningioma Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Meningioma Drugs [https://www.delveinsight.com/sample-request/meningioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Meningioma Companies
NX Development Corp., Clarity Pharmaceutical Ltd., Bristol-Myers Squibb, Biosynthema Inc. , and others.
Meningioma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Subcutaneous
* Intravenous
* Oral
* Intramuscular
* Molecule Type
Meningioma Products have been categorized under various Molecule types such as
* Small molecules
* Natural metabolites
* Monoclonal antibodies
* Product Type
Unveil the future of Meningioma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Meningioma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/meningioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Meningioma Pipeline Report
* Coverage- Global
* Meningioma Companies- NX Development Corp., Clarity Pharmaceutical Ltd., Bristol-Myers Squibb, Biosynthema Inc. , and others.
* Meningioma Pipeline Therapies- Nivolumab, Cabozantinib, Abemaciclib, SOM230C, Bevacizumab, 177Lu-DOTATATE, Pembrolizumab and others.
* Meningioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Meningioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Meningioma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Meningioma Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/meningioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Meningioma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Meningioma - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Meningioma Collaboration Deals
* Late Stage Products (Phase III)
* Gleolan: Nx Development Corp.
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Nivolumab: Bristol-Myers Squibb
* Drug profiles in the detailed report.....
* Pre-clinical and Discovery Stage Products
* Drug profiles in the detailed report.....
* Inactive Products
* Meningioma Key Companies
* Meningioma Key Products
* Meningioma- Unmet Needs
* Meningioma- Market Drivers and Barriers
* Meningioma- Future Perspectives and Conclusion
* Meningioma Analyst Views
* Meningioma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=meningioma-pipeline-appears-robust-with-5-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/meningioma-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Meningioma Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4041303 • Views: …
More Releases from ABNewswire
Hillman Unveils New-Generation Hunting Boots for Men Featuring Dual-Insulation a …
Image: https://www.abnewswire.com/upload/2025/09/ba5edccf338bc4d7305201efbc60a77a.jpg
Hillman, the performance hunting brand trusted by professionals across rugged North American terrain, today announced the release of its next-generation line of hunting boots for men [https://hillmangear.com/collections/hunting-boots-men-s-hunt-footwear], engineered with a dual-insulation system inspired by space technology. The new hunting boots collection features NASA-developed Aerogel Trademark paired with Matrix Registered insulation to deliver arctic-level warmth at a fraction of the weight and bulk of traditional padded boots.
Purpose-built for early season…
Cedric D. Fisher & Company Publishers Releases SIGHT: Groundbreaking Novel Explo …
Cedric D. Fisher & Company Publishers launches SIGHT by Alexandria Clarimond, a literary fiction novel following Elora ("Ellie") through seven decades of life as she confronts progressive blindness from macular degeneration. The novel's innovative "Seven Sight Loss Events" structure parallels physical vision decline with spiritual awakening, creating a powerful meditation on resilience and meaning.
SAN ANTONIO, TX - September 18th, 2025 - Cedric D. Fisher & Company Publishers, a San Antonio-based…
New Launch Protech Systems - A Security System Installation Company in Vancouver …
Protech Systems, a newly launched security system installation company in Vancouver, BC, is now open to serve homeowners and businesses. The company specializes in installing and integrating advanced security solutions, including alarm systems, security cameras, smart home integrations, and monitoring services.
Vancouver, BC - Protech Systems has officially launched in Vancouver, British Columbia, bringing modern home and commercial security solutions to families and business owners across the Lower Mainland. With over…
Soft Tissue Sarcoma Market to Experience Notable Growth in Forecast Span by 2034 …
The Key Soft Tissue Sarcoma Companies in the market include - Epizyme, Blueprint Medicines, Eli Lilly, Philogen, Intensity Therapeutics, Peel Therapeutics, Pure Biologics, Edgewood Oncology, Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, and others.
The Soft Tissue Sarcoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period.…
More Releases for Meningioma
Meningioma Market Report 2032: Epidemiology Analysis, Treatment drugs, FDA Appro …
DelveInsight's "Meningioma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Meningioma, historical and forecasted epidemiology as well as the Meningioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Meningioma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Meningioma market size from 2019 to 2032, segmented by…
Comprehensive Analysis of Meningioma Market 2032: Epidemiological Insights, Trea …
(Albany, USA) DelveInsight's "Meningioma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Meningioma, historical and forecasted epidemiology as well as the Meningioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Meningioma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Meningioma market size from 2019 to 2032,…
Meningioma Market Report 2032: Epidemiology Analysis, Treatment drugs, FDA Appro …
(Albany, USA) DelveInsight's "Meningioma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Meningioma, historical and forecasted epidemiology as well as the Meningioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Meningioma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Meningioma market size from 2019 to…
Meningioma Market is Expected to Show a Healthy Growth Rate During the Study Per …
DelveInsight's "Meningioma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Meningioma, historical and forecasted epidemiology as well as the Meningioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Download Sample Report to know more @ https://www.delveinsight.com/sample-request/meningioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Meningioma Overview
Meningioma, also known as meningeal tumor, is typically a slow-growing tumor that forms from the meninges, the membranous layers surrounding the…
Meningioma Market to Witness Growth by 2032, Estimates DelveInsight | Companies- …
DelveInsight's "Meningioma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Meningioma, historical and forecasted epidemiology as well as the Meningioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Meningioma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Meningioma market size from 2019 to 2032, segmented…
Meningioma Drug Market Sales, Consumption and Forecasts Report 2030
Overview:
A Meningioma Drug Market 2023 research report typically contains an in-depth analysis of a specific market or industry.
The Meningioma Drug Market research report focuses on the industrys major nations sales, development trends, and general consumption patterns. The research focuses on the competitiveness, marketing division, and international Meningioma Drug Market providers.The impact of domestic and major players is also discussed, along with detailed information on market share, new developments and…
